Dr. Thomas LeBlanc on Patient Shared Decision-Making in Hematologic Malignancies

Video

Thomas LeBlanc, MD, assistant professor of medicine, Duke Cancer Institute, discusses why it is important to include patients in the decision-making process for the treatment of hematologic malignancies.

Thomas LeBlanc, MD, assistant professor of medicine, Duke Cancer Institute, discusses why it is important to include patients in the decision-making process for the treatment of hematologic malignancies.

Oncologists have a tendency to give patients a lot of information at once regarding their diagnosis and treatment options. While it is important to give patients this information, oncologists don’t often check back with the patient to make sure they understood and remembered everything they were told, says LeBlanc.

Oncologists should be aware of how much they are talking versus how much the patient is talking and be sure to strike a balance. They should also ask the patient how they like to make decision, if they want to be actively or passively involved, and if they want a recommendation upfront or want to do their own research and come back with questions, says LeBlanc.

<<<

View more from the 2016 NCCN Hematologic Malignancies Congress

Related Videos
Angela Jia, MD, PhD, of University Hospitals
Robert Wang, MD, of Fox Chase Cancer Center
Alexander Kutikov, MD, FACS, of Fox Chase Cancer Center
Roger Li, MD, of Moffitt Cancer Center
Joshua J. Meeks, MD, PhD, of Northwestern University Feinberg School of Medicine
Neal Shore, MD, FACS, of GenesisCare USA and Carolina Urologic Research Center
Mark D. Tyson, II, MD, MPH
Adam S. Faye, MD
Pasi A. Jänne, MD, PhD, discusses an exploratory analysis from the FLAURA2 trial of osimertinib plus chemotherapy in treatment-naive, EGFR-mutant NSCLC.